Toleranzia AB Market Cap ($13.91 Million)
Market Cap & Net Worth: Toleranzia AB (TOL)
Toleranzia AB market cap. Toleranzia AB (ST:TOL) has a market capitalization of $13.91 Million (Skr129.25 Million) as of November 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #26047 globally and #531 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Toleranzia AB's stock price Skr0.48 by its total outstanding shares 270961984 (270.96 Million). Also see how efficiently does Toleranzia AB generate cash for how efficiently the company converts equity into cash flow.
Toleranzia AB Market Cap History (2020–2025)
Toleranzia AB market cap history from 2020 to 2025. Data shows change from $44.47 Million to $13.91 Million (-22.54% CAGR). Check latest Toleranzia AB stock price today for real-time trading data and today's change.
Toleranzia AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Toleranzia AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Toleranzia AB annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.58x
Toleranzia AB's market cap is 0.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $44.47 Million | $12.88 Million | -$4.89 Million | 3.45x | N/A |
| 2021 | $34.41 Million | $27.59 Million | -$6.28 Million | 1.25x | N/A |
| 2022 | $32.66 Million | $35.37 Million | -$8.46 Million | 0.92x | N/A |
| 2023 | $12.48 Million | $50.92 Million | -$7.46 Million | 0.25x | N/A |
| 2024 | $17.32 Million | $30.03 Million | -$9.44 Million | 0.58x | N/A |
Competitor Companies of TOL by Market Capitalization
Companies near Toleranzia AB in the global market cap rankings as of November 4, 2026. Also see TOL total asset value for a full breakdown of the balance sheet.
Key companies related to Toleranzia AB by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #534 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #580 globally with a market cap of $46.03 Billion USD ( CN¥314.55 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #534 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.90 |
| #580 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $46.03 Billion | CN¥49.31 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Toleranzia AB (2020–2025)
Market capitalization of Toleranzia AB from 2020 to today. Between 2020 and today, Toleranzia AB's market cap moved from $44.47 Million to $ 13.91 Million, with a yearly change of -22.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | Skr13.91 Million | -19.70% |
| 2024 | Skr17.32 Million | +38.79% |
| 2023 | Skr12.48 Million | -61.79% |
| 2022 | Skr32.66 Million | -5.08% |
| 2021 | Skr34.41 Million | -22.62% |
| 2020 | Skr44.47 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 18th, 2026 the market cap of Toleranzia AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.91 Million USD |
| MoneyControl | $13.91 Million USD |
| MarketWatch | $13.91 Million USD |
| marketcap.company | $13.91 Million USD |
| Reuters | $13.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Toleranzia AB
Toleranzia AB (publ), a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate in clinical trial for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate for the treatment of ANCA vasculitis, an autoimmune blood vessel disease. In … Read more